搜索
Regenxbio Inc
RGNX添加自选
13.280USD
+0.190+1.45%
收盘 07/02, 13:00（美东）报价延迟15分钟
686.54M总市值
亏损市盈率 TTM
关键数据
13.640今开
14.250最高
3.30M成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
6.48%换手率
13.090昨收
13.165最低
29.30M成交额
亏损市盈率静
6.58市净率
0.00%股息率 TTM
-69.65%ROA
16.19052周最高
2.10量比
-227.10M净利润
50.89M总股本
-5.5953每股收益TTM
1.05Beta
-196.43%ROE
5.45552周最低
8.29%振幅
-73.22%毛利率
686.54M总市值
21.00回报/风险
4.56%风险率
TradingKey Regenxbio Inc股票评分
单位: USD 更新时间: 2026-07-02操作建议
Regenxbio Inc当前公司基本面数据相对谨慎，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名97/387位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价26.25。中期看，股价处于上升通道。近一个月，市场表现很强，技术面评分较高，但很强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Regenxbio Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
极度看好
Regenxbio Inc亮点
亮点风险
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
业绩高增长
公司营业收入稳步增长，连续3年增长88.87%
估值合理
公司最新PE估值-2.37，处于3年历史合理位
机构减仓
最新机构持股45.28M股，环比减少7.13%
ETHSX持仓
明星投资者ETHSX持仓，最新持仓市值62.96K
活跃度增加
近期活跃度增加，过去20天平均换手率1.53
分析师目标
根据
13
位分析师
买入
评级
26.250
目标均价
+121.89%
涨幅空间
Regenxbio Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Regenxbio Inc简介
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
公司代码RGNX
公司Regenxbio Inc
CEOSimpson (Curran M)
网址https://regenxbio.com/
相关品种
热门品种
常见问题
Regenxbio Inc(RGNX)的当前股价是多少？
Regenxbio Inc(RGNX)的当前股价是 13.28。
Regenxbio Inc的股票代码是什么？
Regenxbio Inc的股票代码是RGNX。
Regenxbio Inc股票的52周最高点是多少？
Regenxbio Inc股票的52周最高点是16.19。
Regenxbio Inc股票的52周最低点是多少？
Regenxbio Inc股票的52周最低点是5.46。
Regenxbio Inc的市值是多少？
Regenxbio Inc的市值是675.85M。
现在Regenxbio Inc(RGNX)的股票是买入、持有还是卖出？
根据分析师评级，Regenxbio Inc(RGNX)的总体评级为买入，目标价格为26.25。
Regenxbio Inc(RGNX)股票的每股收益（EPS TTM）是多少
Regenxbio Inc(RGNX)股票的每股收益（EPS TTM）是-3.76。